─ Zealand eligible to receive up to EUR 295 million in potential milestone payments for the first commercialized product plus research funding and royalties. In 2014, payments of EUR 5.6 million to Zealand
[...]
· End of Phase II study in chronic lymphocytic leukemia (CLL)
· Authorization to start Phase II study in chronic myeloid leukemia (CML)
Paris, 16 July 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutic [...]
Amsterdam, the Netherlands, 10 July 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces the fourth investment of its Health Economics Fund (LSP HEF) in Rotation Medical, a private [...]
Amsterdam, the Netherlands, 10 July 2014. It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company arGEN-X was successfully listed on th [...]
Breda, the Netherlands / Ghent, Belgium, 8 July 2014 – arGEN-X N.V. (“arGEN-X”), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatm [...]
Amsterdam, the Netherlands, 8 July 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces the third investment of its Health Economics Fund (LSP HEF) in Mint Solutions Holding BV, a [...]
SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA en [...]
Espoo, Finland - Mendor, a leading diabetes technology company, is pleased to
announce it has completed a new series of growth financing for further global
expansion totaling € 6,5 Million. The financing cam [...]
Leiden, The Netherlands, June 25, 2014 - Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the suc [...]
Results are presented today at the 17th Vitamin D Workshop in Chicago, USA
Paris, 20 June 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on the
Alternext market of Euronext in Paris, [...]
─ Zealand eligible to receive up to EUR 295 million in potential milestone payments for the first commercialized product plus research funding and royalties. In 2014, payments of EUR 5.6 million to Zealand
[...]
· End of Phase II study in chronic lymphocytic leukemia (CLL)
· Authorization to start Phase II study in chronic myeloid leukemia (CML)
Paris, 16 July 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutic [...]
Amsterdam, the Netherlands, 10 July 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces the fourth investment of its Health Economics Fund (LSP HEF) in Rotation Medical, a private [...]
Amsterdam, the Netherlands, 10 July 2014. It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company arGEN-X was successfully listed on th [...]
Breda, the Netherlands / Ghent, Belgium, 8 July 2014 – arGEN-X N.V. (“arGEN-X”), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatm [...]
Amsterdam, the Netherlands, 8 July 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces the third investment of its Health Economics Fund (LSP HEF) in Mint Solutions Holding BV, a [...]
SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA en [...]
Espoo, Finland - Mendor, a leading diabetes technology company, is pleased to
announce it has completed a new series of growth financing for further global
expansion totaling € 6,5 Million. The financing cam [...]
Leiden, The Netherlands, June 25, 2014 - Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the suc [...]
Results are presented today at the 17th Vitamin D Workshop in Chicago, USA
Paris, 20 June 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on the
Alternext market of Euronext in Paris, [...]
Follow us
